Cargando…
Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients
BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes h...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246507/ https://www.ncbi.nlm.nih.gov/pubmed/34262784 http://dx.doi.org/10.1177/20552173211022767 |
_version_ | 1783716327757709312 |
---|---|
author | Held, Friederike Kalluri, Sudhakar Reddy Berthele, Achim Klein, Ana-Katharina Reindl, Markus Hemmer, Bernhard |
author_facet | Held, Friederike Kalluri, Sudhakar Reddy Berthele, Achim Klein, Ana-Katharina Reindl, Markus Hemmer, Bernhard |
author_sort | Held, Friederike |
collection | PubMed |
description | BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes have been reported to be associated with MOG-Ab. OBJECTIVE: To investigate the seroprevalence of MOG-Ab under consideration of demographics, disease entities and time course in a large cohort of unselected neurological patients. METHODS: Blood samples of 2.107 consecutive adult neurologic patients admitted to our department between 2016-2017 were tested for MOG-Ab using a cell-based assay. MOG-Ab persistence was analyzed in follow-up samples. External validation was performed in two independent laboratories. RESULTS: We found MOG-Ab in 25 of 2.107 (1.2%) patients. High antibody ratios were mostly associated with NMOSD and MOG-AD phenotype (5/25). Low ratios occurred in a wide range of neurological diseases, predominantly in other demyelinating CNS diseases (5/25) and stroke (6/25). MOG-Ab persistence over time was not confined to NMOSD and MOG-AD phenotype. CONCLUSION: The present study demonstrates the occurrence of MOG-Ab in a wide range of neurological diseases. Only high MOG-Ab ratios were associated with a defined clinical phenotype, but low MOG-Ab ratios were not. The diagnostic value of low MOG-Ab is thus highly limited. |
format | Online Article Text |
id | pubmed-8246507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82465072021-07-13 Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients Held, Friederike Kalluri, Sudhakar Reddy Berthele, Achim Klein, Ana-Katharina Reindl, Markus Hemmer, Bernhard Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is recognized as a distinct nosological entity. IgG antibodies against MOG (MOG-Ab) overlap with neuromyelitis optica spectrum disorders (NMOSD) phenotype in adults. However, an increasing number of clinical phenotypes have been reported to be associated with MOG-Ab. OBJECTIVE: To investigate the seroprevalence of MOG-Ab under consideration of demographics, disease entities and time course in a large cohort of unselected neurological patients. METHODS: Blood samples of 2.107 consecutive adult neurologic patients admitted to our department between 2016-2017 were tested for MOG-Ab using a cell-based assay. MOG-Ab persistence was analyzed in follow-up samples. External validation was performed in two independent laboratories. RESULTS: We found MOG-Ab in 25 of 2.107 (1.2%) patients. High antibody ratios were mostly associated with NMOSD and MOG-AD phenotype (5/25). Low ratios occurred in a wide range of neurological diseases, predominantly in other demyelinating CNS diseases (5/25) and stroke (6/25). MOG-Ab persistence over time was not confined to NMOSD and MOG-AD phenotype. CONCLUSION: The present study demonstrates the occurrence of MOG-Ab in a wide range of neurological diseases. Only high MOG-Ab ratios were associated with a defined clinical phenotype, but low MOG-Ab ratios were not. The diagnostic value of low MOG-Ab is thus highly limited. SAGE Publications 2021-06-25 /pmc/articles/PMC8246507/ /pubmed/34262784 http://dx.doi.org/10.1177/20552173211022767 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Paper Held, Friederike Kalluri, Sudhakar Reddy Berthele, Achim Klein, Ana-Katharina Reindl, Markus Hemmer, Bernhard Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title_full | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title_fullStr | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title_full_unstemmed | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title_short | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
title_sort | frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients |
topic | Original Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246507/ https://www.ncbi.nlm.nih.gov/pubmed/34262784 http://dx.doi.org/10.1177/20552173211022767 |
work_keys_str_mv | AT heldfriederike frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients AT kallurisudhakarreddy frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients AT bertheleachim frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients AT kleinanakatharina frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients AT reindlmarkus frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients AT hemmerbernhard frequencyofmyelinoligodendrocyteglycoproteinantibodiesinalargecohortofneurologicalpatients |